A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation
International Journal of Molecular Sciences · 20.03.2024 · 25 (6) · 3482
DOI: 10.3390/ijms25063482 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.03.2024. Verfasst von Maciej Naumowicz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland. Hauptthemen laut MEDLINE: Necrobiosis Lipoidica, Diabetes Mellitus, Type 1, Dermatologic Agents, Biological Products. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok.
Abstract (Originalsprache)
Necrobiosis lipoidica (NL) is a rare granulomatous disease of a not fully understood etiopathogenesis. Classically, NL is associated with insulin-dependent diabetes mellitus. The disease often fails to respond to conventional treatments and adversely affects patients’ quality of life. First-line medications are usually topical corticosteroids, but patients respond to them with varying degrees of success. Other options include tacrolimus, phototherapy, cyclosporine, fumaric acid esters, and biologics (adalimumab, etanercept, and infliximab). Our review aims to present new therapeutic approaches potentially effective in patients with refractory lesions, describe the presumed etiopathogenesis, and provide diagnostic guidance for clinicians. The review concludes that Janus kinase inhibitors and biologics such as ustekinumab and secukinumab can be used effectively in patients with recalcitrant NL. Another promising treatment option is tapinarof (an aryl hydrocarbon receptor agonist). However, studies on larger groups of patients are still needed to evaluate the effectiveness of different therapeutic options and to define consistent treatment regimens for NL. It is advisable to improve the awareness of physicians of various specialties regarding necrobiosis lipoidica as lesions diagnosed earlier usually have a better response to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland.
ORCID-Profile: Stefan Modzelewski, Anna Baran, Iwona Flisiak
Förderung
- Medical University of Białystok
Zitieren
APA
Naumowicz, M., Modzelewski, S., Macko, A., Łuniewski, B., Baran, A., & Flisiak, I. (2024). A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation. International Journal of Molecular Sciences, 25(6), 3482. https://doi.org/10.3390/ijms25063482
Vancouver
Naumowicz M, Modzelewski S, Macko A, Łuniewski B, Baran A, Flisiak I. A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation. International Journal of Molecular Sciences. 2024;25(6):3482. doi:10.3390/ijms25063482
BibTeX
@article{Naumowicz2024,
author = {Naumowicz, Maciej and Modzelewski, Stefan and Macko, Angelika and Łuniewski, Bartosz and Baran, Anna and Flisiak, Iwona},
title = {A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3482},
doi = {10.3390/ijms25063482}
}
EUVIMED